Cameron Cook: How Cost-Effective Is Evolocumab for Patients at High Cardiovascular Risk?
Cameron Cook, Senior HEOR Health Economist, Olpasiran HEOR Global Product Lead at Amgen, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in medRxiv, adding:
”Pleased to share a new preprint I co-authored, now available on medRxiv:
‘Cost-effectiveness of Evolocumab in Patients at High Cardiovascular Risk Without a Previous Myocardial Infarction or Stroke’
Using a Markov state health-economic model informed by cardiovascular outcomes evidence, the study projected improved cardiovascular outcomes and quality-adjusted survival with evolocumab added to standard therapy, and at the direct-to-patient price, remained cost-effective (significantly below AHH/ACC thresholds) across the base case and all scenario analyses evaluated.
Grateful to all fellow co-authors for the collaboration.
This manuscript is a preprint and has not yet undergone peer review.”
Title: Cost-effectiveness of Evolocumab in Patients at High Cardiovascular Risk Without a Previous Myocardial Infarction or Stroke
Authors: Gregg C. Fonarow, Cameron Cook, Eduard Sidelnikov, Sushmitha Inguva, Ajay Bhatia, Guillermo Villa
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?